Survodutide
Also known as: BI 456906, Dual GLP-1/Glucagon
The Dual Agonist for Weight & Liver Health
Dual GLP-1/glucagon receptor agonist showing impressive results for both weight loss and liver fat reduction. A promising alternative to tirzepatide with a different dual mechanism.
How It Works
Simple Explanation
Activates both GLP-1 and glucagon receptors - GLP-1 for appetite suppression and glucagon for increased fat burning and liver fat reduction.
Technical Details
Dual agonist targeting GLP-1R for appetite/satiety regulation and GCGR for enhanced hepatic lipid oxidation, thermogenesis, and metabolic rate. The glucagon component provides additional energy expenditure benefits and potent effects on liver fat.
Pharmacokinetics & Storage
Half-Life
~5-6 days (estimated)
Duration in circulation
Storage Requirements
Not commercially available - currently only accessible through clinical trials
Research Timeline: What Studies Have Observed
Based on clinical trial data and published research. Individual responses may vary significantly.
Weeks 1-4
Phase 2 data showed early appetite suppression. GI adaptation period with titration.
Weeks 5-12
Studies observed significant weight loss momentum with continued dose escalation.
Weeks 13-24
Research documented robust weight loss and improvements in liver fat markers.
Weeks 24-46
Phase 2 trials showed up to 18.7% weight loss with notable NASH improvements.
Benefits
- Up to 18.7% body weight loss in Phase 2
- Significant liver fat reduction
- Potential NASH/MASH treatment
- Improved metabolic parameters
- Weekly injection convenience
Potential Side Effects
Nausea
Common (30-40%)
Improves with titration
Vomiting
Common (15-20%)
Diarrhea
Common (15%)
Decreased appetite
Common
Known Interactions
Based on clinical research and pharmacological studies. Always consult a healthcare provider about potential interactions.
Diabetes Medications
cautionAs with other incretin mimetics, blood sugar management medications may need adjustment.
Insulin
cautionResearch protocols adjusted insulin dosing to prevent hypoglycemia.
Research Highlights
Phase 2 Obesity Trial (2024)
Up to 18.7% body weight loss at 46 weeks with dose-dependent efficacy
View StudyMASH/NASH Study (2024)
Significant liver fibrosis improvement and potential for MASH resolution without worsening fibrosis
View StudyFrequently Asked Questions
How does survodutide differ from tirzepatide?
When might survodutide be available?
Is survodutide better for fatty liver?
Can I get survodutide outside clinical trials?
Who Is It For
- Those interested in cutting-edge weight loss options
- Patients with fatty liver disease/NASH
- Those who may benefit from glucagon-mediated fat burning
- Research compound enthusiasts
Who Should Avoid
- Those needing FDA-approved treatments now
- Medullary thyroid carcinoma history
- Severe GI conditions
- Pregnant/planning pregnancy
How It Compares
Research-based comparisons with similar peptides. Individual responses and circumstances should guide decisions.
Tirzepatide is FDA-approved with proven efficacy. Different dual mechanism (GIP instead of glucagon). Currently the most practical choice while survodutide remains investigational.
Retatrutide is a triple agonist (GLP-1/GIP/glucagon) potentially offering benefits of both mechanisms. Also still investigational.
Semaglutide is FDA-approved with extensive long-term data. Single mechanism but proven safety and efficacy profile.
Research Dosing Protocols
Common Research Protocol
Titrated up to 4.8mg weekly (Phase 3 doses under investigation)
Administration Frequency (per studies)
Once weekly
Delivery Methods
Available Forms
- • Subcutaneous injection
💡 Currently in clinical trials - dosing protocols being optimized
⚠️ Not Medical Advice: Dosing information is compiled from published research and clinical studies for educational purposes only. This is not a recommendation. All peptide research should be conducted by qualified professionals in controlled research environments. Consult a healthcare provider before considering any protocol.
Cost Context
Not commercially available - currently only accessible through clinical trials. If approved, pricing likely similar to other premium GLP-1 agonists.
Prices vary by region, source, and insurance coverage. This is general context only.
Related Peptides
Tirzepatide outperforms semaglutide in head-to-head trials. As a dual GLP-1/GIP agonist, people are losing 20-25% body weight.
Triple agonist hitting GLP-1, GIP, and glucagon receptors. Phase 2 trials showed 24% weight loss with emerging anti-cancer data.
If you've heard of Ozempic, you've heard of semaglutide. Originally for Type 2 diabetes, it became a phenomenon when people started losing 15-20% of their body weight.
⚠️ Important Disclaimer
This information is for educational purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use by the FDA. Always consult with a qualified healthcare provider before starting any peptide protocol. PepGains does not sell peptides and is not responsible for how this information is used. All timeline and efficacy information is based on published research and clinical trials - individual results may vary significantly.